Sugi Predict

Sugi Predict / Compounds / Cingestol

Cingestol

Cingestol

SCHEMBL282508

C#C[C@]1(O)CC[C@H]2[C@@H]3CC=C4CCCC[C@@H]4[C@H]3CC[C@@]21C

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 6/20 0.72
▸ PGR P06401 6/20 0.72
▸ LMNA P02545 5/20 0.72
▸ CYP2C19 P33261 3/20 0.72
▸ ALDH1A1 P00352 3/20 0.72
▸ HIF1A Q16665 2/20 0.72
▸ OPRK1 P41145 2/20 0.72
▸ MAOA P21397 1/20 0.72
▸ CYP1A2 P05177 1/20 0.72
▸ CYP2C9 P11712 1/20 0.72
▸ ESR1 P03372 10/20 0.58
▸ SLC6A4 P31645 5/20 0.58
▸ ABCB11 O95342 4/20 0.58
▸ SHBG P04278 3/20 0.58
▸ NR3C1 P04150 3/20 0.58
▸ TSHR P16473 1/20 0.58
▸ ADRA2A P08913 1/20 0.58
▸ PDK1 Q15118 1/20 0.56
▸ PDK2 Q15119 1/20 0.56
▸ PDK3 Q15120 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cingestol SCHEMBL12178106 1.00 CYP3A4 (0.72) CYP3A4PGRLMNACYP2C19ALDH1A1
Lynestrenol SCHEMBL9699960 0.84 PGR (1.00) CYP3A4PGRLMNACYP2C19ALDH1A1
Lynestrenol SCHEMBL16180701 0.84 PGR (1.00) CYP3A4PGRLMNACYP2C19ALDH1A1
Lynestrenol SCHEMBL37816 0.84 PGR (1.00) CYP3A4PGRLMNACYP2C19ALDH1A1
Lynestrenol SCHEMBL11575942 0.83 PGR (0.98) CYP3A4PGRLMNACYP2C19ALDH1A1
Bolenol SCHEMBL636530 0.82 ESR1 (0.71) CYP3A4PGRLMNACYP2C19ALDH1A1
Bolenol SCHEMBL636531 0.82 ESR1 (0.71) CYP3A4PGRLMNACYP2C19ALDH1A1
SCHEMBL15164705 0.82 CYP3A4 (0.57) CYP3A4PGRLMNACYP2C19ALDH1A1
SCHEMBL15164626 0.82 CYP3A4 (0.57) CYP3A4PGRLMNACYP2C19ALDH1A1
SCHEMBL15153019 0.82 CYP3A4 (0.57) CYP3A4PGRLMNACYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 723 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3863708-B1 MIXED IONIC CONDUCTORS AND CORRESPONDING DEVICES, SYSTEMS AND METHODS OF MAKING BATTELLE MEMORIAL INSTITUTE (US) 2024-09-11 — — EP claimed
US-20160008376-A1 Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders BIOCOPEA LIMITED (GB) 2016-01-14 — — US claimed
WO-2016005599-A1 COMPOSITIONS, METHODS AND USES FOR TREATING GENDER-BIASED IMMUNE DISORDERS BIOCOPEA LIMITED (GB) 2016-01-14 — — WO claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
US-8268352-B2 Modified release composition for highly soluble drugs TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-18 — — US claimed
US-8263125-B2 Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-11 — — US claimed
US-20110003748-A1 Method of treatment and compositions of D-chiro inositol and phosphates thereof JENNINGS-SPRING BARBARA L 2011-01-06 — — US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
US-7662987-B2 Oxidation of 1-acyl alkyl compound under anhydrous condition XENOPORT, INC. (US) 2010-02-16 — — US claimed
US-20090214474-A1 Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development JENNINGS BARBARA BROOKE 2009-08-27 — — US claimed
EP-0539493-A1 TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES. BODOR NICHOLAS S (US) 1993-05-05 — — EP claimed
WO-1992017185-A1 TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES UNIVERSITY OF FLORIDA (US) 1992-10-15 — — WO claimed
WO-1992000988-A1 TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES BODOR NICHOLAS S (US) 1992-01-23 — — WO claimed
EP-0222425-A2 Brain-specific drug delivery UNIVERSITY OF FLORIDA (US) 1987-05-20 — — EP claimed
EP-0218300-A2 Brain-specific drug delivery UNIVERSITY OF FLORIDA (US) 1987-04-15 — — EP claimed
US-4540564-A DIHYDROPYRIDINE AND/OR PYRIDINIUM SALT REDOX CARRIER UNIVERSITY OF FLORIDA (US) 1985-09-10 — — US claimed
EP-0110955-A1 BRAIN-SPECIFIC DRUG DELIVERY. UNIV FLORIDA (US) 1984-06-20 — — EP claimed
WO-1983003968-A1 BRAIN-SPECIFIC DRUG DELIVERY UNIVERSITY OF FLORIDA (US) 1983-11-24 — — WO claimed
US-4016270-A Method for treating dysmenorrhea with a uterine therapeutic system ALZA CORPORATION (US) 1977-04-05 — — US claimed
US-4014988-A Method for treating hypermenorrhea with uterine therapeutic system ALZA CORPORATION (US) 1977-03-29 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003748-A1 Method of treatment and compositions of D-chiro inositol and phosphates thereof PPIP5K2, SHBG, CYP24A1 CYP3A4 4420/4885PGR 364/4885LMNA 939/4885
US-20090214474-A1 Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development SHH, ERH, CDK5 CYP3A4 4636/4885PGR 915/4885LMNA 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback